Graphic of a newly published research article published in The Journal of Clinical Investigation titled 'Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells' by Brittain et al.

Could RNA-targeting identify drivers of AR-V7 linked #ProstateCancer?

A team including Prof de Bono @icr.ac.uk, supported by our Movember London Centre of Excellence, share new findings as part of a @jci.org double-header.

Grab a ☕ and read: bit.ly/4cjfadS

Impaired #vitaminD signaling reveals #neutrophils as key drivers of #ProstateCancer dissemination

🗞️ doi.org/10.1038/s44321-026-00417-5
by K. Len-Tayon, @gilleslaverny.bsky.social & colleagues @igbmc.bsky.social

Ana Paula Sousa, representing the Portuguese Psychologists’ Association (OPP), highlighted how health literacy can transform prostate cancer prevention and care.

Let’s keep working together to build more informed, patient-centered healthcare across Europe!

#ProstateCancer #HealthLiteracy

📢 Upcoming European Prostate Cancer Alliance webinar!

This webinar will focus on epigenetics in #ProstateCancer, with confirmed speakers including Prof Wilbert Zwart @zwartlab.bsky.social, Prof Leigh Ellis, and Filipa Moreira Silva.

📆 Monday 22 June 2026, 15:00-17:15

Men over 40, are you listening? Our mate @willmcdonald9 from Channel 9 has a life-saving question: Do you know your PSA?

A simple blood test changed everything for him. Early detection is the goal. Talk to your GP. 🩺

#ProstateCancer #KnowYourPSA #MensHealth #WillMcDonald

Report: 2026 cancer rates to remain high in Canada The findings underscore the need for caregivers to stay informed regarding incidence of the disease.

Cancer rates in Canada for 2026 are projected to remain high, particularly for lung, breast, prostate, and colorectal cancers -- which will likely make up 47% of new diagnoses #radiology #prostatecancer #breastcancer #colorectalcancer #lungcancer buff.ly/Hnu9YyM

Web-Based Personalized Machine Learning Recommendations to Enhance Shared Decision-Making in Prostate-Specific Antigen Screening: Randomized Controlled Trial Background: Prostate‑specific antigen (PSA) screening involves complex trade‑offs between early detection and the risks of overdiagnosis. For older adults (aged ≥50 years), shared decision‑making (SDM) is often hindered by limited health literacy, sensory or cognitive impairments, and multimorbidity, which complicate risk comprehension. Traditional decision aids provide foundational knowledge but are often nonpersonalized. Machine learning (ML) may offer individualized recommendations, yet the psychological and behavioral effects of ML‑assisted SDM in geriatric populations remain poorly characterized. Objective: This study aimed to develop and evaluate a web‑based, ML‑driven decision aid integrated into an SDM workflow to provide personalized PSA screening recommendations and to assess its effects on decisional conflict (primary outcome), state anxiety, and decision satisfaction among middle‑aged and older men. Methods: The study followed a 2‑stage design. First, a model establishment group (n=507) was used to train and evaluate 6 ML algorithms based on clinical and values‑clarification data. A random forest model was selected for its superior performance (mean area under the curve 0.933, SD 0.350; 95% CI 0.902-0.963). Second, a randomized controlled trial was conducted with 367 participants (mean age 64.34, SD 10.30 years) randomly assigned 1:1 to the ML suggestion group (MLSG; n=185) or the control group (CG; n=182). Both groups received video‑based education, counseling, and values clarification; only the MLSG received an ML‑generated “second opinion” recommendation. Primary and secondary outcomes were assessed using the Decisional Conflict Scale (DCS), Spielberger State‑Trait Anxiety Inventory (STAI), and Satisfaction with Decision scale. Results: In the randomized controlled trial (n=367), the MLSG reported significantly lower decisional conflict than the CG (total DCS score: mean difference [MD] –3.77, 95% CI –5.55 to −1.99; Cohen =–0.44; P

New in JMIR Aging: Web-Based Personalized Machine Learning Recommendations to Enhance Shared Decision-Making in Prostate-Specific Antigen Screening: Randomized Controlled Trial #MachineLearning #PersonalizedHealthcare #SharedDecisionMaking #HealthLiteracy #ProstateCancer

How can AI help personalize #prostatecancer care?

Hear from Dr. Laura Chang on the PCUK Vanguard Study, how the #ArteraAI Prostate Test works, and Ian’s story.

With @ProstateUK + partners @UniofOxford @BristolUni @UofGlasgow

EMBARK in biochemically recurrent prostate cancer: a journey for some but not most EMBARK was a pivotal multi-institutional trial that sought to move the clinical paradigm for initiating enzalutamide with/without androgen deprivation ther

“Given known tox of ADT-based strategies in #ProstateCancer, overtreatment of #BCR could… bring more near-term harms than benefits…individualized approaches…which factors in PSA in the context of PSADT… while excluding presumptive use of PSMA data…”

shorturl.at/MB0JN

#EMBARK in #BCR #ProstateCancer: a Journey for Some but NOT Most
By Dr. Melissa Abel et al.

“EMBARK was a biomarker-selected study enrolling pts @ the greatest risk…based on PSADT…required a PSADT≤ 9 mos…data suggests the true benefits are in pts w/PSADT≤ 6mos”

shorturl.at/MB0JN

Metformin Slows Prostate Cancer Growth and Simulates Exercise Could a cheap drug for diabetes prevent or improve survival from many diverse cancers? Metformin appears to slow prostate cancer growth!

Metformin Slows Prostate Cancer Growth and Simulates Exercise www.peoplespharmacy.com/articles/why... via @peoplespharmacy

#metformin #prostate #prostatecancer #cancer #health

TULSA Gives New Options for Intermediate-Risk Prostate Cancer TULSA (transurethral ultrasound ablation), a treatment option for people with prostate cancer, has fewer side effects than some other procedures.

A non-invasive treatment called TULSA is giving some men with intermediate-risk prostate cancer a new option with fewer side effects. Progress in cancer care is not always about doing more, but doing better.
#ProstateCancer #MedicalInnovation #CancerCare #TCSC
www.hopkinsmedicine.org/news/article...

#MolecularImaging in Focus Series: The First Three Episodes
www.diagnosticimaging.com/view/molecul...
#radiology #RadRes #NuclearMedicine #ProstateCancer

Radium-223 Treatment Outcomes in Patients with Metastatic Castration-Resistant #ProstateCancer :

A Taiwan-Japan Collaborative Cohort Study

www.sciencedirect.com/science/arti... #OpenAccess #cancer

#trends today for 'prostate cancer' 'japanese prime' & 'max verstappen'

Click/Tap below:

www.newsmason.com?query=%22pro...

www.newsmason.com?query=%22jap...

www.newsmason.com?query=%22max...

#prostatecancer #japaneseprime #maxverstappen

Metformin Raises Exercise-Associated Metabolite Lac-Phe in Prostate Cancer Patients on Hormone Therapy A new study from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine found that the common diabetes drug metformin can increase levels of N-lactoyl-phenylalanine (Lac-Phe), a metabolite typically elevated after intense exercise. This effect was observed in prostate cancer patients, even when they were not physically active. Led by Dr. Marijo Bilusic and colleagues, the research published in EMBO Molecular Medicine shows that metformin mimics one key metabolic signal associated with exercise. Lac-Phe is produced when lactate combines with phenylalanine during periods of metabolic demand and has been linked to appetite regulation and weight control. In the study, patients taking metformin showed Lac-Phe levels similar to those seen after strenuous exercise, despite the metabolic disruptions caused by hormone therapy, which often leads to fatigue, weight gain, and increased cardiovascular risk. Importantly, the rise in Lac-Phe did not correlate with anti-tumor effects as measured by PSA levels, indicating it primarily supports metabolic health rather than directly fighting the cancer. The findings were consistent across different metabolic therapies. Researchers emphasize that while metformin is not a replacement for exercise, it may help counter treatment-related metabolic strain when physical activity is limited. Co-authors including Priyamvada Rai and David B. Lombard highlighted the importance of addressing whole-patient metabolic health during cancer care. This transdisciplinary work connects clinical observations with molecular biology, offering potential new strategies to improve quality of life for prostate cancer patients undergoing hormone therapy.

Metformin Raises Exercise-Associated Metabolite Lac-Phe in Prostate Cancer Patients on Hormone Therapy

🤖 IA: It's not clickbait ✅
👥 Usuarios: It's not clickbait ✅

#metformin #prostatecancer #metabolism

View full AI summary:

Real-world validation is key for AI in oncology.

This study highlights multimodal and image-only digital pathology biomarkers validated using multi-institutional data, an important step toward clinical adoption.

Learn more: buff.ly/n4nHxqy

#ProstateCancer #ArteraAI

My father was just diagnosed with prostate cancer.

My uncle on my mom’s side died from it.

It’s hereditary and it’s deadly but easily addressed if caught on time.

Latino men, get your prostate checked. ✅ 🏥

#ProstateCancer #Cancer #CancerSucks #Health #Disabilities

Fig. 2. Representative treatment plan of salvage proton (compared with photon) SBRT for locally recurrent PCa. 30 Gy to whole gland + 40 Gy SIB to DIL at base/seminal vesicle junction. (Left) proton plan, (Center) photon plan, (Right) excess bladder, penile and rectal radiation with photons compared to protons.

Up to half of #prostatecancer recurrences following #EBRT occur exclusively within the prostate - read a #PTCOG Genitourinary Subcommittee evaluation of the advantages & challenges of PT for radio-recurrent prostate cancer: www.sciencedirect.com/science/arti...

Life expectancy matters in prostate cancer decisions—but it’s not always discussed. This study highlights key barriers: concerns about patient receptiveness, communication challenges, and low confidence in LE estimates @TimDaskivich #JGIM #ProstateCancer rdcu.be/e1mpt

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial Along with the known survival benefits, the clinically meaningful delays in pain progression and time to deterioration of overall wellbeing support consideration of darolutamide plus ADT as a standard-of-care treatment option in patients with mHSPC.

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive #prostatecancer (ARANOTE): secondary and exploratory analyses www.thelancet.com/journals/lan... #Cancer

April 10,2026

ALL GOOD THINGS…🥹

Thx🙏🏽 to the patients & so many amazing people @thenci & beyond in my 21+yrs

Many good Friends on the Journey

Dr. Melissa Abel continues the research:#PSMA+ #BCR & #cytokines #ProstateCancer #immunotherapy

The future @ NCI is bright☀️

World Health Day, 7 April. Prevention begins with knowledge.

Prevention begins with knowledge.

This #WorldHealthDay, the CLEAR-PC project emphasizes the role of health literacy in prostate cancer prevention and care.

Join us to improve health literacy:
🔗 www.clearpc.eu/stakeholders

#CLEARPC #EU4Health #HealthLiteracy #ProstateCancer

Our newest #ProstateCancer #supportgroup is here. Gay or bisexual men diagnosed with prostate cancer have particular concerns. Addressing them with your peers is far easier! 🏳️‍🌈
2nd Sundays 5:00pm ET
www.gotomeet.me/ancanschmier

Who’s most at risk for prostate cancer, and how is treatment evolving?

This episode breaks down risk factors, screening, and how care is becoming more personalized.

Listen here: buff.ly/WikqXR0

#ProstateCancer #ArteraAI #PrecisionMedicine

One year ago today, completed 28 days of radiation treatment for early onset prostate cancer. Cured. PSA down from 8.1 to 0.69. Shout out to @cityofhope.bsky.social in #Temecula for an amazing job, team, support and follow ups. Not dead yet :) #Prostate #prostatecancer

@garethrichards.bsky.social @sheffielduni.bsky.social wants to develop new, innovative ways to monitor and treat #ProstateCancer.

In 2022, we funded Gareth to explore adrenomedullin as a biomarker and therapeutic target for prostate cancer.

📙Read more here: prostatecanceruk.org/research/res...

📣The anti-obesogenic metabolite, Lac-Phe, is elevated by #metformin treatment in #ProstateCancer patients

By M. Bilusic, D. Lombard, P. Rai & colleagues at University of Miami Miller School of Medicine

🗞️ doi.org/10.1038/s44321-026-00408-6

Original post on indieweb.social

So hopeful for these trials to create a vaccine for some of the deadliest of #cancer:

“BNT122 is the candidate more ambitious...A sample of the patient's tumor is taken, the genome is sequenced to identify up to 20 unique mutations,& a personalized mRNA vaccine is built that contains the […]

Some thoughts on the management of #BCR #ProstateCancer #EMBARK

Coming 🔜 in The Oncologist w/Dr. Melissa Abel & Dr. Fatima Karzai

“EMBARK In Biochemically Recurrent Prostate Cancer: A Journey for Some but not Most”